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Abstract 
Introduction: The aim of the study was an assessment of longitudinal changes in fracture probability in postmenopausal women.
Material and methods: A group of 226 postmenopausal women at baseline mean age 66.46 ± 7.96 years were studied. There were 21 women 
without therapy, 102 taking calcium + vitamin D, and 103 women on antiresorptive therapy, in the study group. Data concerning clinical 
risk factors for osteoporosis and hip BMD were gathered. Fracture probability for major and hip fractures was established using FRAXTM.
Results: Mean follow-up time was 2.43 ± 0.59 years. Baseline FRAX value in the whole group for major fracture was 7.1 ± 4.18, 
and at follow-up it was 7.44 ± 4.04. Respective results for FRAX for hip fracture were 3.17 ± 2.69 and 3.02 ± 2.35. In the whole group the 
probability for major fractures significantly increased during follow-up (p < 0.05) and for hip fracture did not change. In non-treated 
patients and patients taking calcium + vitamin D the fracture probability increased significantly. In patients on antiresorptive therapy the 
fracture probability did not change, which was connected with an improvement in bone status assessed by DXA. Femoral neck T-score 
in the whole group did not change, in those not treated and taking calcium + vitamin D it decreased significantly (p < 0.05), while in 
treated women it increased significantly (p < 0.05). In patients with improved bone status the FRAX values for major and hip fractures 
decreased by 0.44 ± 1.62 and 0.36 ± 1.19, respectively. Conversely, in patients with worsening T-score value the FRAX values increased 
by 1.33 ± 1.42 and 0.66 ± 1.25, respectively.
Conclusion: Antiresorptive therapy stabilises fracture probability in postmenopausal women due to improvement in bone status. 
(Endokrynol Pol 2019; 70 (6): 473–477)
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Introduction
The key problem in osteoporotic individuals is risk of 
fracture. Fractures are commonly the result of minimal 
trauma, e.g. a fall from standing height. Late conse-
quences of fractures include limitations in functional 
status, and hip or spine fractures increase mortality. 
Osteoporotic fractures cause significant costs for health 
systems. One should remember that prior fracture in-
creases the risk of subsequent fracture, being one of the 
most important clinical risk factors. Therefore, avoiding 
the first fracture should be a primary goal in the man-
agement of osteoporotic patients. Fracture risk depends 
on several clinical risk factors (age, sex, some medica-
tions or underlying diseases) and bone status. Some of 
them are modifiable, the others are unmodifiable. Some 
years ago, a tool called FRAX for fracture risk assess-
ment was developed by Kanis et al. [1]. FRAX combines 
some clinical risk factors and femoral neck BMD and 
is corrected by estimated lifetime, and the final result 
is a fracture probability. FRAX was developed in order 
to establish fracture probability in treatment-naive 
patients, and some thresholds for initiation of therapy 
were proposed. Fracture risk calculated by FRAX is used 
as a threshold for initiation of pharmacological therapy. 
In recent recommendations, FRAX values exceeding 3% 
for hip fracture and 10% for major fracture are thresh-
olds recommended for the onset of pharmacological 
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expressed as root-mean-square coefficient of variation (CV%). CV% 
values calculated for Zabrze, Warsaw, and Łódź were: 1.83%, 1.48%, 
and 0.90%, respectively.
Fracture probability for hip and major fractures was established 
using the Polish version of FRAX. 
Each patient received therapeutic recommendations from their 
physician according to individual assessment.
Table I shows the clinical characteristics of the studied women. 
Among them were 21 patients without therapy (subgroup 1), 102 
taking calcium + vit. D (subgroup 2), and 103 on antiresorptive 
therapy and calcium + vitamin D (subgroup 3). The most common 
medication used was ibandronic acid (n = 43) followed by alendro-
nate (n = 28) and risedronate (n = 25). Generally, the medications 
did not change in the duration of the study.
The mean age did not differ among subgroups.
Local Ethics Committees approved the study protocols, and each 
woman gave written, informed consent. 
Results
Mean follow-up was 2.43 ± 0.59 years in the whole 
group. Mean follow-up in subgroups 1, 2, and 3 were 
2.08 ± 0.31, 2.49 ± 0.61, and 2.43 ± 0.6 years, respective-
ly. Follow-up was significantly shorter in the untreated 
women than in the other subgroups (p < 0.01) and did 
not differ between subgroups 2 and 3. The number of 
clinical risk factors did not change significantly during 
follow-up (data not shown).
Table II includes the results for fracture probability 
for major and hip fractures in the whole group and in 
subgroups. The baseline fracture probability differed 
significantly between subgroups, being the lowest in 
the untreated women and the highest in those receiv-
ing antiresorptive treatment. The same obvious trend 
concerns bone densitometry results. In regard to 
longitudinal changes in the whole group, the fracture 
probability increased for major fracture (p < 0.01), and 
the hip fracture probability did not change. In untreated 
women major and hip fractures probability increased 
therapy by Camacho et al. [2]. After some discussion 
and with the awareness of limitations of FRAX [3, 4], 
the same thresholds were proposed in Poland by Lorenc 
et al. [5], and they remain valid [6]. One may expect 
that baseline fracture probability in efficiently treated 
patients should diminish or stabilise at follow-up. In 
several studies medications used in osteoporosis de-
crease fracture incidence, so one may expect that also 
fracture probability should decrease. In our previous 
study in a retrospective analysis performed in a group 
of 191 postmenopausal women, we proved that anti-
resorptive therapy may be considered as profitable for 
skeletal status, as was shown by Puskiewicz et al. [7]. 
In previously mentioned recommendations the change 
in longitudinal FRAX values was one of the criteria of 
therapeutic efficacy [2].
In the current study we analysed in a longitudinal 
observation whether therapy for osteoporosis is able 
to diminish fracture probability expressed by FRAX.
Material and methods
In the study a group of 226 postmenopausal women were observed. 
They were recruited in Polish outpatient osteoporotic clinics in War-
saw (n = 88), Łódź (n = 79), and Zabrze (n = 59). All women were 
treatment naive at baseline. Data on clinical risk factors necessary 
for the calculation of fracture probability according to FRAX were 
collected at baseline and follow-up. At baseline in 101 patients no 
clinical risk factors were present, one risk factor was present in 88, 
two in 29, three in seven, and four risk factors were present in one 
woman. Seventy-nine (34.9%) women reported at enrolment that 
they had experienced at least one osteoporotic fracture previously. 
Twenty-four of them had had multiple fractures (two fractures were 
reported by 15 subjects, three fractures by eight subjects, and four 
fractures by one woman).
Bone status at the proximal femur was established using Hologic 
Explorer (Zabrze) and Lunar GE (Warsaw and Łódź) densitom-
eters at baseline and at follow-up. Precision of measurements was 
established separately for the above-mentioned DXA devices and 
Table I. Clinical characteristic of women studied — all women and subgroups (mean, SD)
Whole  
group 
(n = 226)
Untreated  
women
Subgroup 1 (n = 21)
Women on calcium 
and vitamin D
Subgroup 2 (n = 102)
Women on 
antiresorptive therapy
Subgroup 3 (n = 103)
Age [years] at baseline 66.6 ± 7.96 67.3 ± 7.1 66.4 ± 7.3 66.5 ± 8.8
Age [years] at follow-up 69.0 ± 8.02 69.4 ± 7.1 68.9 ± 7.3 69.0 ± 8.9
Weight [kg] at baseline 67.35 ± 12.6 75.0 ± 15.3 69.7 ± 11.8 63.5 ± 11.6
Weight [kg] at follow-up 67.7 ± 13.2 74.6 ± 15.6 70.2 ± 12.2 63.9 ± 12.5
Height [cm] at baseline 158.1 ± 5.9 160.4 ± 5.0 158.4 ± 5.6 157.3 ± 6.2
Height [cm] at follow-up 157.6 ± 5.9* 160.1 ± 5.2 158.0 ± 5.7* 156.7 ± 6.2**
BMI [kg/m2] at baseline 26.9 ± 4.9 29.2 ± 6.0 27.8 ± 4.7 25.6 ± 4.5
BMI [kg/m2] at follow-up 27.3 ± 5.1^ 29.1 ± 6.2 28.1 ± 4.9^^ 26.1 ± 4.9^^
Previous fracture at baseline 79 (34.9%) 2 (9.5%) 29 (28.4%) 48 (46.6%)
BMI — body mass index; *significantly lower than at baseline, p < 0.0001; **significantly lower than at baseline, p < 0.01; ^significantly higher than at baseline,  
p < 0.01; ^^significantly higher than at baseline, p < 0.05
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(p < 0.05 and < 0.01, respectively). Also, in subgroup 
2 both major and hip fracture probability increased 
(p < 0.0001). In subgroup 3 the FRAX values did not 
change significantly.
Femoral neck (FN) T-score in the whole group did 
not change. In subgroups 1 and 2 it decreased signifi-
cantly (p < 0.05), and in subgroup 3 it increased signifi-
cantly from -2.13 ± 0.71 to -2.05 ± 0.63 (p < 0.05) (Tab. 
II). In 127 (56%) women the T-score increased, and in 
99 (44%) it decreased during follow-up. In patients with 
improved bone status the FRAX values for major and 
hip fractures decreased by 0.44 ± 1.62 and 0.36 ± 1.19, 
respectively. Conversely, in patients with worse T-
score the FRAX values increased by 1.33 ± 1.42 and 
0.66 ± 1.25, respectively. A comparison of longitudinal 
changes in FRAX values in these subgroups (n = 127 
and n = 99) shows significant differences (p < 0.0001).
Figures 1 and 2 present correlations between longitu-
dinal changes in FRAX and FN T-score. For both fracture 
probability variables an improvement was significantly 
connected with an improvement in bone status.
During follow-up eight fractures were observed 
(four in patients with prior fracture and four in women 
without prior fracture), but due the small number of 
fractures this factor was not analysed. Those new frac-
tures were recognised in the forearm (3), spine (2), and 
other skeletal sites (3).
Discussion
The most important finding of the current longitudinal 
study is the observation that in women treated with 
antiresorptive agents the fracture probability did not 
change during the period of observation. Adequate 
data in other patients not receiving the antiresorptive 
therapy showed an increase in fracture probability. 
We consider that the current observations support 
the efficacy of pharmacological management and 
are important for practitioners. The improvement in 
fracture probability was connected with the positive 
influence of patients’ management on bone status. In-
creasing age negatively influences fracture probability, 
so even in a case of stable BMD, the FRAX value will 
increase. Such an observation of positive influence 
on bone status and secondary stabilisation in frac-
ture probability clearly indicates the main direction 
in management. One may hypothesise that fracture 
probability would change also when the number of 
clinical risk factors changes. In the current study we 
did not observe longitudinal changes in regard to the 
number of clinical risk factors. Therefore, the only 
factor positively influencing fracture probability was 
an improvement in bone status. Current results are 
consistent with our previous data obtained in retro-
spective analysis in a group of 191 women [7]; in this 
study the correlation between changes in FRAX for 
major fracture with changes in T-score was slightly 
stronger than in the current study (–0.76 vs. –0.66, 
p < 0.05) while FRAX for hip fracture was almost the 
same (0.631 vs. 0.613, non-significant). We consider that 
a positive influence on bone status was responsible for 
a good response to treatment measured by the level 
of fracture probability. These observations are clearly 
visible in Figures 1 and 2.
Table II. Results for fracture probability according to FRAX for major and hip fractures and for FN T-scores in the whole group 
and in subgroups at baseline and follow-up (mean, SD). Differences between subgroups and between baseline and follow-up 
are shown
Whole 
 group 
(n = 226)
Untreated  
women
Subgroup 1 (n = 21)
Women on calcium  
and vitamin D
Subgroup 2 (n = 102)
Women on 
antiresorptive therapy
Subgroup 3 (n = 103)
Major fracture at baseline (%) 7.1 ± 4.18 3.88 ± 1.4* 6.05 ± 2.88@ 8.79 ± 4.87
Major fracture at follow-up (%) 7.44 ± 4.04 4.3 ± 1.65* 6.61 ± 2.93@ 8.91 ± 4.7
p value# 0.01 0.05 0.0001 NS
Hip fracture at baseline (%) 2.16 ± 2.23 0.63 ± 0.52** 1.46 ± 1.31@ 3.17 ± 2.69
Hip fracture at follow-up (%) 2.25 ± 2.04 0.84 ± 0.72** 1.76 ± 1.53@ 3.02 ± 2.35
p value# NS 0.01 0.0001 NS
FN T-score at baseline –1.71 ± 0.81 –0.85 ± 0.76*** –1.48 ± 0.67@@ –2.13 ± 0.71
FN T-score at follow-up –1.74 ± 0.72 –1.02 ± 0.74*** –1.58 ± 0.63@@ –2.05 ± 0.63
p value# NS 0.05 0.05 0.05
NS — non significant; #for comparison between follow-up and baseline examination; *significantly lower than in women on calcium +  vitamin D supplementation 
(p < 0.001) and in women on antiresorptive therapy (p < 0.0001); **significantly lower than in women on calcium + vitamin D supplementation (p < 0.01) and 
in women on antiresorptive therapy (p < 0.0001); ***significantly higher than in women on calcium + vitamin D supplementation (p < 0.001) and in women on 
antiresorptive therapy (p < 0.0001); @significantly lower than in women on antiresorptive therapy (p < 0.0001); @@significantly higher than in women on antiresorptive 
therapy (p < 0.0001)
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In a longitudinal four-year study 11,049 untreated 
women aged over 50 years were given antiosteoporotic 
therapy by Leslie et al. [8]. Information about clinical risk 
factors for osteoporosis were gathered along with BMD 
measurements. At baseline, FRAX for major fracture was 
8.2% and increased to 9.6% at the final point. Respec-
tive data for hip were 1.1% and 1.6%, respectively. We 
noted in patients treated by antiresorptive medication 
only a small, non-significant increase in FRAX for major 
fracture and a non-significant decrease for hip FRAX 
(Tab. II). In the cited study the FN T-score decreased 
from –1.6 to –1.7, and we observed a small but significant 
increase. Similarly to the current study, the authors did 
not observe changes in the number of clinical risk fac-
tors. Probably the longer follow-up in comparison to our 
study revealed a stronger influence of ageing.
Lo
ng
itu
di
na
l c
ha
ng
e 
in
 m
aj
or
 fr
ac
tu
re
 p
ro
ba
bi
lit
y 
as
se
ss
ed
 b
y 
FR
AX
10
8
6
4
2
0
–2
–4
–6
–8
–10
Longitudinal change in T-score value for remoral neck
–1.6 –1.2 –0.8 –0.4 0 0.4 0.8 1.2
Figure 1. Relationships between change in major fracture probability assessed by FRAX and change in T-score value for femoral neck 
during the follow-up period
Figure 2. Relationships between change in hip fracture probability assessed by FRAX and change in T-score value for femoral neck 
during the follow-up period
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Of course, the most important point concerns 
fracture incidence in a longitudinal observation. In 
the current study the number of new fractures was 
too small, so this criterion cannot be verified, and 
further follow-up should take into consideration the 
fracture incidence. We should also remember that 
patients were non-randomly allocated into subgroups 
in regard to the kind of management. Due to such 
pattern of patients’ allocation to the analyzed groups, 
the study design may be considered more adhere to 
everyday practice. Therefore, the results of the current 
observation have significance for practitioners. One 
might expect that the FRAX algorithm would prop-
erly predict fracture incidence. In a study performed 
in 815 Japanese women by Tamaki et al. [9] a 10-year 
follow-up observed that the fracture rate did not 
differ significantly from that predicted by FRAX [9]. 
FRAX was also compared with other screening tools 
to identify women with increased risk of fracture [10, 
11]. In a population-based, prospective study per-
formed in Denmark by Rubin et al. [10], comprising 
3614 women, FRAX did not give better fracture risk 
prediction than several different screening methods 
(OST, ORAI, OSIRIS, SCORE, and age alone). Also, 
a fragility index had predictive power comparable to 
FRAX in women from the Global Longitudinal Study 
in Women (GLOW) [11]. Another algorithm for frac-
ture prediction — QFractureScores by Hippisley-Cox 
et al. [12] — was evaluated in a prospective study 
by Collins et al. [13]. This study showed predictive 
power for fracture for QFracturesScores.
Our study has some limitations. The number of sub-
jects studied and duration of follow-up did not allow 
us to gather a sufficient number of fractures necessary 
to prove longitudinal efficacy in regard to fracture in-
cidence. In particular, the number of women without 
therapy was small. During the study, the treatment 
recommendations for patients enrolled in each of the 
three participating centers could have been different, 
depending on the physicians' experience and prefer-
ences.
The follow-up was significantly shorter in the un-
treated women than in other subgroups. We consider 
that further analysis performed in larger groups with 
longer follow-up will establish both stabilisation in 
fracture probability and a decrease in fracture incidence.
Conclusion
Antiresorptive therapy stabilises fracture probability 
in postmenopausal women due an improvement in 
bone status.
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